None listed
Conditions
Interventions
Intervention1: LI12507F1: Dose: 2 capsules (each capsule containing 400 mg of novel botanical formulation (LI12507F1) and excipients QS)
Frequency: BD
Duration: 112 Days
Route of Administration: Oral
Sponsors
Laila Nutraceuticals
Eligibility
Inclusion criteria
Inclusion criteria: • Subjects who signs the Informed Consent Form • Male or female subjects between 21 to 50 years of age • Subject with BMI range (27-32) • Ability to understand the risks/benefits of the protocol • Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera ®, or double-barrier and have a negative pregnancy test at the Screening Visit. Female subjects of non-childbearing potential must be amenorrheic for at least 1 years or had a hysterectomy and/or bilateral oophorectomy. • Willingness to participate in a walking-exercise program (5 days a week, 30 min per day) during the course of the study. • Subject agrees to consume a vegetarian/non-vegetarian diet of approximately 2,000 kcal/day (17% protein, 25% Fat and 58% carbohydrate). • Subject should be available for duration of study period (6-8 months) • Subject agrees to come to site in fasting state for their weight measurement and other laboratory parameters examination in all the scheduled visits. • Subject using other therapies for weight management including physiotherapy/ occupational therapy agrees to discontinue these therapies during this study. • Subject agrees not to start any new therapies for weight loss during the course of the study. • Subjects willing to go for DEXA analysis during the course of study. • Subjects agree to maintain the activity dairy
Exclusion criteria
Exclusion criteria: • Subjects suffered from intractable obesity, had defined weight limits or had experienced any recent, unexplained weight loss or gain • Subjects having history of underlying inflammatory arthropathy septic arthritis inflammatory joint disease,gout,pseudo gout, Pagets disease,joint fracture, acromegaly, fibromyalgia, Wilsons disease, ochronosis, hemochromatosis, heritable arthritic disorder or collagen gene mutations or rheumatoid arthritis • Subjects having history of asthma • Subjects having history of cardiovascular diseases • Subjects having history of diabetes (Type I or Type II) - except other than the subject having the pre-diabetes condition with the fasting blood glucose between 100 to 125 mg/dl or random blood glucose = 140-199 mg/dl. • Subject with Hyperuricaemia (males > 480 µmol/L, females > 450 µmol/L). • Subjects having thyroid disease. • Subjects having abnormal liver or kidney function tests (ALT or AST > 2 times the upper limit of normal; elevated Creatinine, males > 125 µmol/L, females > 110 µmol/L). • Subjects having abnormal findings on complete blood count. • Subjects having history of coagulopathies. • Subjects with hypertension. • Subjects with HIV Positive. • Subjects having history of congestive heart failure. • Subjects having history high alcohol intake ( >2 standard drinks per day). • Pregnant, breast feeding or planning t become pregnant during the study. • Subjects having history of psychiatric disorder that may impair the ability of subjects to provide written informed consent. • Subjects participated in any investigational study medication with in thirty (30) days prior to screening • Any other condition that, in the opinion of the investigator, would adversely affect the subjects ability to complete the study or its measures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Body WeightTimepoint: Week 0, Week 2, Week 4, Week 8, Week 12 and Week 16 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from the baseline to the end of the treatment period in : • Reduction of BMI, Waist Hip ratio and improvement in Lean Body Mass measured through DEXA scan •LDL, HDL, VLDL, TGL and Total Cholesterol •Change in Serum biomarkers like Adiponectin, Leptin, Ghrelin and Insulin Timepoint: Week 0, Week 2, Week 4, Week 8, Week 12 and Week 16 | — |
Countries
India
Contacts
Public ContactShekhar Gupta
Laila Nutraceuticals
Outcome results
None listed